Breast cancer
Advanced HER2-positive/HER2-low breast cancer
Patient with brain metastasis and stable extracranial disease: when to change antiHER2-based therapy
Patient with active brain metastasis: locoregional therapy vs systemic therapy
Patient with active brain metastasis: T-DXd vs.
tucatinib-based therapy
Can we use TDM1 after T-DXd
Role of repeated biopsies to guide ADCs in HER2-low BC
Moderator: Shereef Elsamany
Panel:
Role of anthracyclines in early breast cancer
- When to omit anthracyclines in(neo) adjuvant therapy of HER2-negative breast cancer
When to use anthracyclines in (neo) adjuvant therapy of HER2-positive breast cancer
Moderator:Dr. Meteeb Alfohaidi
Panel:
Satellite Symposium
Can we de-escalate axillary surgery/omit adjuvant radiotherapy with excellent response after NAC?
Complete response to NAC
Residual ITCs after NAC
Controversies of targeted axillary dissection
SLNB: Negative LNs in frozen section/positive in final pathology
Negative SLNB after neoadjuvant hormonal therapy
Moderator:Dr. Nasser Ali Al-Dhaibani Dr. Roaa Attieh
Panel:
Opening ceremony
Lunch & prayer
Satellite Symposium
Oncologists/pathologists dialogue TILS and descalation of systemic therapy in early breast cancer?
Moderator: Dr. Ahmed Alwbari Dr. Hatim Al Maghrabi
Genomic tools in breast cancer
- chemotherapy in high risk lobular/mucinous BC?
- Neoadjuvant therapy in premenopausal patients with lobular BC?
Adjuvant therapy with node negative and node positive lobular BC?
Adjuvant therapy in luminal BC with RS 16-25?
Can genomic tools guide adjuvant cdk4-6 inhibitors in N0/N1 tumours?? - Oncotype DX and selection of neoadjuvant hormonal vs chemotherapy therapy
- Role of interval Ki67 assessment with neoadjuvant hormonal therapy
Moderator: Ahmed Alshehri
Panel:
Break
Transition from hormonal-based to chemotherapy in metastatic BC??
- Patients with early progression on CDK4-6 inhibitors: What is next??
- When to start ADCs/olaparib in patients who had visceral crisis?? Can be upfront??
- Any role of hormonal monotherapy after CDK4-6 inhibitors??
- Biomarkers to guide subsequent therapies
- Can we use one ADC after previous ADC??
Moderator: Dr. Ahmed Alfaraj
Panel:
Concluding remarks Day 1
Setting-up clinical trials in Middle east: Challenges and opportunities
Moderators:
Dr. Emad Tashkandi Dr. Hosam Alghanmi
Panel:
Pancreatic cancer
- Neoadjuvant therapy in resectable/borderline resectable pancreatic cancer
- Best neoadjuvant strategy
- 1st line and subsequent therapies in pancreatic cancer: Doublet vs Triplets
- biomarkers for metastatic patients
Moderator: Dr. Abdullah Alsharm
Panel:
Biliary tract cancer
- Immunetherapy in advanced BTC: Yes/No
- Which agent?
- Patient selection/tumour location?
- Role of maintenance therapy?
- Role of liquid biopsy/biomarker assessment
Moderator: Dr. Mohammed Algarni
panel:
Break
Perioperative therapy in Gastric cancer
- Role of laparoscopy assessment before perioperative therapy?
- What to do in patients with poor response to neoadjuvant therapy?
- Role of biomarkers e.g MSI in decision-making before perioperative therapy?
- Patients with limited peritoneal metastasis: Role of HIPEC?
- Role of immunetherapy with perioperative therapy non-metastatic gastric cancer?
Moderator: Dr. Fahad Ibnshamsah
Challenges and dynamics of oncology health care
- Financial toxicities and economic burden
- Delayed access to oncology care
- Cancer survivors: challenges and special requirements
- Integration of service with primary health care for cancer survivors
Moderator: Dr. Esam Murshid
Panel:
Immunetherapy in CRC: Transition from metastatic to early stage
Satellite Symposium
Closing remarks
Prayer &Lunch